{"id":"cetirizine","rwe":[],"_fda":{"id":"322eb217-089d-e92d-e063-6394a90a6566","set_id":"013ce40e-37c9-4b84-b530-ed895f60ce0e","openfda":{"upc":["0300450239129"],"unii":["64O047KTOA"],"route":["ORAL"],"rxcui":["2558501","2558503"],"spl_id":["322eb217-089d-e92d-e063-6394a90a6566"],"brand_name":["Childrens Zyrtec"],"spl_set_id":["013ce40e-37c9-4b84-b530-ed895f60ce0e"],"package_ndc":["50580-790-01","50580-790-02","50580-790-03"],"product_ndc":["50580-790"],"generic_name":["CETIRIZINE HYDROCHLORIDE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["CETIRIZINE HYDROCHLORIDE"],"manufacturer_name":["Kenvue Brands LLC"],"application_number":["NDA021621"],"is_original_packager":[true]},"purpose":["Purpose Antihistamine"],"version":"8","stop_use":["Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away."],"warnings":["Warnings Do not use if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine. Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose. Ask a doctor or pharmacist before use if you are taking tranquilizers or sedatives. When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away. If pregnant or breast-feeding if breast-feeding: not recommended if pregnant: ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)"],"questions":["Questions? call 1-800-343-7805 (toll-free) or 215-273-8755 (collect)"],"ask_doctor":["Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose."],"do_not_use":["Do not use if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine."],"when_using":["When using this product drowsiness may occur avoid alcoholic drinks alcohol, sedatives, and tranquilizers may increase drowsiness be careful when driving a motor vehicle or operating machinery"],"effective_time":"20250407","active_ingredient":["Active ingredient (in each chewable tablet) Cetirizine HCl 2.5 mg"],"inactive_ingredient":["Inactive ingredients betadex, corn starch, flavor, lactose monohydrate, magnesium stearate, mannitol, silicified microcrystalline cellulose, sucralose"],"storage_and_handling":["Other information store between 20° to 25°C (68° to 77°F) do not use if blister unit is torn or broken"],"indications_and_usage":["Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat"],"ask_doctor_or_pharmacist":["Ask a doctor or pharmacist before use if you are taking tranquilizers or sedatives."],"spl_unclassified_section":["Drug Facts"],"dosage_and_administration":["Directions may be taken with or without water chew or crush tablets completely before swallowing children 2 to under 6 years of age Chew and swallow 1 tablet (2.5 mg) once daily; If needed, dose can be increased to a maximum of 2 tablets (5 mg) once daily or 1 tablet (2.5 mg) every 12 hours. Do not give more than 2 tablets (5 mg) in 24 hours. adults and children 6 years and over Chew and swallow 2 tablets (5 mg) or 4 tablets (10 mg) once daily depending upon severity of symptoms; do not take more than 4 tablets (10 mg) in 24 hours. adults 65 years and over Chew and swallow 2 tablets (5 mg) once daily; do not take more than 2 tablets (5 mg) in 24 hours. children under 2 years of age ask a doctor consumers with liver or kidney disease ask a doctor"],"spl_product_data_elements":["Childrens Zyrtec Cetirizine hydrochloride BETADEX STARCH, CORN LACTOSE MONOHYDRATE MAGNESIUM STEARATE MANNITOL SUCRALOSE CETIRIZINE HYDROCHLORIDE CETIRIZINE CTZ"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding if breast-feeding: not recommended if pregnant: ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)"],"dosage_and_administration_table":["
children 2 to under 6 years of ageChew and swallow 1 tablet (2.5 mg) once daily; If needed, dose can be increased to a maximum of 2 tablets (5 mg) once daily or 1 tablet (2.5 mg) every 12 hours. Do not give more than 2 tablets (5 mg) in 24 hours.
adults and children 6 years and overChew and swallow 2 tablets (5 mg) or 4 tablets (10 mg) once daily depending upon severity of symptoms; do not take more than 4 tablets (10 mg) in 24 hours.
adults 65 years and overChew and swallow 2 tablets (5 mg) once daily; do not take more than 2 tablets (5 mg) in 24 hours.
children under 2 years of ageask a doctor
consumers with liver or kidney diseaseask a doctor
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL New look Same relief NDC 50580-790-01 Children's ZYRTEC ® Cetirizine HCl chewable tablets 2.5 mg /antihistamine ALLERGY Indoor + Outdoor Allergies 2 yrs & older Dye-Free Chewables 24 Hour Relief of Sneezing Runny Nose Itchy, Watery Eyes Itchy Throat or Nose Actual Size Grape Flavor Chew or crush tablets completely before swallowing 12 CHEWABLE TABLETS Zyrtec-1"]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"21451 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"18714 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"15812 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"13880 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"13143 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"12556 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"12309 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"11854 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"11029 reports"},{"date":"","signal":"ABDOMINAL DISCOMFORT","source":"FDA FAERS","actionTaken":"10469 reports"}],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Chronic renal failure syndrome","Coronary arteriosclerosis","Diabetes mellitus","Disease of liver","Drowsy","Glaucoma","Hemodialysis with High-Flux Membrane","Hypertensive disorder","Hypertensive urgency","Hyperthyroidism","Kidney disease","Retention of urine"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT00240032","NCT00974571","NCT01064115","NCT06819774","NCT01134328","NCT02132169","NCT05946551","NCT00649857","NCT00826943","NCT02543346","NCT03192488","NCT01495338","NCT00610584","NCT05275933","NCT03047278","NCT04237090","NCT00257582","NCT07461727","NCT06039137","NCT06126991","NCT01127620","NCT02932774","NCT01103050","NCT04935515","NCT01318681","NCT00776139","NCT02604212","NCT00504933","NCT04612803","NCT00851344","NCT04990388","NCT00561717","NCT00253058","NCT07472413","NCT03340740","NCT00864279","NCT04179461","NCT00517946","NCT01241214","NCT00794378","NCT00488176","NCT00637455","NCT04175834","NCT00474890","NCT00866788","NCT01685242","NCT00257569","NCT02756624","NCT03296358","NCT03167216"],"aliases":["Zyrtec","Reactine","Alerid"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0277/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$10","description":"CETIRIZINE HCL 1 MG/ML SOLN","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=cetirizine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:40:16.263141+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:40:22.358767+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:40:15.319948+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cetirizine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:40:22.650488+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:40:14.204851+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:40:14.204880+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:40:24.188398+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:40:23.686036+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1607273/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:40:23.346965+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021621","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:40:14.204884+00:00"}},"allNames":"zyrtec","offLabel":[],"timeline":[],"aiSummary":"Zyrtec, also known as cetirizine, is a small molecule that acts as a histamine H1 receptor antagonist. It is used to treat conditions such as allergic rhinitis, and its effects typically begin within thirty minutes and last for about a day.","brandName":"Zyrtec","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2","novelty":"","modality":"Small molecule","drugClass":"Second-generation antihistamine","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:40:25.651414+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally UCB Pharma)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cetirizine","indications":{"approved":[{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic idiopathic urticaria","diseaseId":"chronic-idiopathic-urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Common cold","diseaseId":"common-cold","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal congestion","diseaseId":"nasal-congestion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal discharge","diseaseId":"nasal-discharge","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Seasonal allergic rhinitis","diseaseId":"seasonal-allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sneezing","diseaseId":"sneezing","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vasomotor rhinitis","diseaseId":"vasomotor-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00240032","phase":"Phase 4","title":"A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Au","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","isPivotal":false,"enrollment":80,"indication":"Multiple Sclerosis","completionDate":"2006-07"},{"nctId":"NCT00974571","phase":"Phase 3","title":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":1365,"indication":"Perennial Allergic Rhinitis","completionDate":"2002-05"},{"nctId":"NCT01064115","phase":"Phase 1","title":"A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":30,"indication":"Healthy","completionDate":"2006-02"},{"nctId":"NCT06819774","phase":"Phase 3","title":"Efficacy and Safety of Cetirizine Hydrochloride Injection in the Treatment of Acute Urticaria: a Randomized, Double-blind, Positive Controlled, Multicenter Phase III Clinical Study","status":"RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","isPivotal":true,"enrollment":284,"indication":"Acute Urticaria","completionDate":"2025-08"},{"nctId":"NCT01134328","phase":"Phase 2","title":"A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allerge","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","isPivotal":false,"enrollment":83,"indication":"Allergic Conjunctivitis","completionDate":"2010-07"},{"nctId":"NCT02132169","phase":"Phase 3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatri","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","isPivotal":true,"enrollment":512,"indication":"Atopic Disease (Including Allergic Conjunctivitis)","completionDate":"2014-10"},{"nctId":"NCT05946551","phase":"Phase 3","title":"Feasibility Assessment of a Decentralized Platform Adaptive Double-Blind, Randomized Controlled Trial Investigating Repurposed Drugs in the Treatment of Post-Acute Sequelae of Coronavirus-19 (PASC)","status":"TERMINATED","sponsor":"Emory University","isPivotal":true,"enrollment":5,"indication":"COVID-19","completionDate":"2024-06-24"},{"nctId":"NCT00649857","phase":"Phase 1","title":"Single-Dose Food In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec® (10 mg; Pfizer) in Healthy Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":18,"indication":"Healthy","completionDate":"2002-12"},{"nctId":"NCT00826943","phase":"Phase 4","title":"Is Levocetirizine Less Sedating Than Cetirizine? A Randomized, Double-blind, Placebo Controlled Trial.","status":"COMPLETED","sponsor":"Vanderbilt University","isPivotal":false,"enrollment":30,"indication":"Allergic Rhinitis","completionDate":"2009-05"},{"nctId":"NCT02543346","phase":"Phase 4","title":"Comparability and Standardization of Controlled Allergen Challenge Facilities","status":"COMPLETED","sponsor":"Queen's University","isPivotal":false,"enrollment":98,"indication":"Allergic Rhinitis","completionDate":"2016-05"},{"nctId":"NCT03192488","phase":"Phase 4","title":"Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia","status":"COMPLETED","sponsor":"Indiana University","isPivotal":false,"enrollment":13,"indication":"Hypoxia, Altitude","completionDate":"2018-06-06"},{"nctId":"NCT01495338","phase":"Phase 1","title":"","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","isPivotal":false,"enrollment":60,"indication":"Normal Ocular Health","completionDate":"2011-12"},{"nctId":"NCT00610584","phase":"NA","title":"Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","isPivotal":false,"enrollment":422,"indication":"Seasonal Allergic Rhinitis","completionDate":"2011-04"},{"nctId":"NCT05275933","phase":"Phase 2","title":"Assessing the Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang as Adjuvant Treatment in Mild COVID-19 Patients on Home Recovery Program in Singapore: a Randomised, Double-blind, Placebo-controlled","status":"COMPLETED","sponsor":"Singapore Chung Hwa Medical Institution","isPivotal":true,"enrollment":93,"indication":"COVID-19","completionDate":"2023-11-22"},{"nctId":"NCT03047278","phase":"Phase 4","title":"Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain.","status":"COMPLETED","sponsor":"Natalia Valadares de Moraes","isPivotal":false,"enrollment":29,"indication":"Neuropathic Pain, Type 2 Diabetes Mellitus","completionDate":"2019-07-01"},{"nctId":"NCT04237090","phase":"Phase 3","title":"Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","isPivotal":true,"enrollment":27,"indication":"Breast Cancer, Lung Cancer","completionDate":"2020-09-04"},{"nctId":"NCT00257582","phase":"Phase 3","title":"Long-term Study of Cetirizine Dry Syrup in Children Suffering From Various Type of Cutaneous Disease Accompanied With Pruritus.","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":60,"indication":"Pruritus","completionDate":""},{"nctId":"NCT07461727","phase":"Phase 1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Adv","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","isPivotal":false,"enrollment":15,"indication":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","completionDate":"2029-01-31"},{"nctId":"NCT06039137","phase":"N/A","title":"The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment: 'The H1-SWITCH Study'","status":"COMPLETED","sponsor":"Erasmus Medical Center","isPivotal":false,"enrollment":395,"indication":"Solid Tumor","completionDate":"2023-10-31"},{"nctId":"NCT06126991","phase":"Phase 1","title":"Organ Protective Effect of Histamine H1 Receptor Antagonist In Patients With Severe Burns: A Clinical Study","status":"UNKNOWN","sponsor":"Ruijin Hospital","isPivotal":false,"enrollment":32,"indication":"Burns","completionDate":"2025-12-31"},{"nctId":"NCT01127620","phase":"Phase 3","title":"A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-ter","status":"COMPLETED","sponsor":"Faes Farma, S.A.","isPivotal":true,"enrollment":650,"indication":"Perennial Allergic Rhinitis","completionDate":"2006-11"},{"nctId":"NCT02932774","phase":"Phase 4","title":"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment ","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","isPivotal":false,"enrollment":683,"indication":"Allergic Rhinitis, Hay Fever","completionDate":"2001-07"},{"nctId":"NCT01103050","phase":"Phase 2","title":"A Randomized, Double-blind, Double-dummy, Placebo Controlled Three-period Incomplete Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine on Total Nasal Symptom Scor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":60,"indication":"Allergic Rhinitis","completionDate":"2010-07-28"},{"nctId":"NCT04935515","phase":"NA","title":"C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.","status":"COMPLETED","sponsor":"Manimarane Arjunan, MD,DM (Cardiology)","isPivotal":false,"enrollment":25,"indication":"COVID -19","completionDate":"2021-06-06"},{"nctId":"NCT01318681","phase":"NA","title":"Effects of Treated and Untreated Allergic Rhinitis on Mood, Cognitive Functions and Actual Driving Performance","status":"COMPLETED","sponsor":"Maastricht University Medical Center","isPivotal":false,"enrollment":22,"indication":"Seasonal Allergic Rhinitis, Driving Ability","completionDate":"2012-10"},{"nctId":"NCT00776139","phase":"NA","title":"An Open Label, Randomized, Single-Center, Single-Dose, Two-Treatment, Two-Period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","isPivotal":false,"enrollment":32,"indication":"Healthy","completionDate":"2004-12"},{"nctId":"NCT02604212","phase":"Phase 2","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With E","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","isPivotal":false,"enrollment":32,"indication":"Hepatitis B","completionDate":"2016-12"},{"nctId":"NCT00504933","phase":"Phase 3","title":"Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.","status":"COMPLETED","sponsor":"Faes Farma, S.A.","isPivotal":true,"enrollment":683,"indication":"Seasonal Allergic Rhinitis","completionDate":"2005-11"},{"nctId":"NCT04612803","phase":"N/A","title":"Observational Study of the Prevalence of Antihistamine Responsive Gastrointestinal Symptoms in Patients Diagnosed With Irritable Bowel Syndrome With Diarrhea","status":"UNKNOWN","sponsor":"University of Cincinnati","isPivotal":false,"enrollment":100,"indication":"Irritable Bowel Syndrome, Dermatographism","completionDate":"2021-08-01"},{"nctId":"NCT00851344","phase":"Phase 2","title":"A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and ","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":54,"indication":"Rhinitis, Allergic, Seasonal","completionDate":"2008-11"},{"nctId":"NCT04990388","phase":"Phase 1","title":"A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD III","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","isPivotal":false,"enrollment":9,"indication":"Glycogen Storage Disease Type III","completionDate":"2023-03-20"},{"nctId":"NCT00561717","phase":"Phase 4","title":"A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal A","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":70,"indication":"Seasonal Allergic Rhinitis","completionDate":"2008-02"},{"nctId":"NCT00253058","phase":"Phase 3","title":"Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Perennial Allergic Rhinitis-","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":286,"indication":"Rhinitis, Allergic, Perennial","completionDate":""},{"nctId":"NCT07472413","phase":"Phase 3","title":"Cetirizine Versus Diphenhydramine as a Pre-medication: Tolerability and Safety in Patients With MS Receiving Anti-Cluster of Differentiation 20 (CD20) Infusion Therapy","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","isPivotal":true,"enrollment":60,"indication":"Multiple Sclerosis","completionDate":"2028-07-01"},{"nctId":"NCT03340740","phase":"Phase 4","title":"The Effect of Cetirizine on Bronchoconstriction in Patients With Allergic Rhinitis and Wheezing in the Pediatric Emergency Department","status":"COMPLETED","sponsor":"New York City Health and Hospitals Corporation","isPivotal":false,"enrollment":40,"indication":"Allergic Rhinitis, Asthma","completionDate":"2021-08-30"},{"nctId":"NCT00864279","phase":"Phase 1","title":"Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Actavis Inc.","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":"2006-09"},{"nctId":"NCT04179461","phase":"Phase 2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma: Bench to Community","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","isPivotal":false,"enrollment":21,"indication":"Asthma in Children","completionDate":"2019-10-03"},{"nctId":"NCT00517946","phase":"N/A","title":"An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in S","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":21,"indication":"Seasonal Allergic Rhinitis, Sinusitis","completionDate":"2007-04"},{"nctId":"NCT01241214","phase":"Phase 2","title":"A Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group, Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","isPivotal":false,"enrollment":579,"indication":"Seasonal Allergic Rhinitis","completionDate":"2011-02"},{"nctId":"NCT00794378","phase":"Phase 3","title":"A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":202,"indication":"Allergic Rhinitis","completionDate":"2004-11"},{"nctId":"NCT00488176","phase":"Phase 4","title":"Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis","status":"UNKNOWN","sponsor":"Medical University of Lodz","isPivotal":false,"enrollment":116,"indication":"Seasonal Allergic Rhinitis","completionDate":"2013-12"},{"nctId":"NCT00637455","phase":"Phase 4","title":"Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":72,"indication":"Seasonal Allergic Rhinitis","completionDate":"2005-01"},{"nctId":"NCT04175834","phase":"Phase 3","title":"Comparing the Risk and Severity of Infusion-Related Reactions in Patients Premedicated With Cetirizine Versus Diphenhydramine Prior to Ocrelizumab Infusions","status":"COMPLETED","sponsor":"Providence Health & Services","isPivotal":true,"enrollment":19,"indication":"Multiple Sclerosis, Infusion Reaction","completionDate":"2022-05-13"},{"nctId":"NCT00474890","phase":"NA","title":"A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy's Reproducibility of a Combination of Pseudoephedrine and Cetirizine on Symptom Scores and Rhinomanometry in Patie","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","isPivotal":false,"enrollment":70,"indication":"Atopy, Rhinitis","completionDate":"2008-02"},{"nctId":"NCT00866788","phase":"Phase 2","title":"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihist","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":90,"indication":"Chronic Idiopathic Urticaria","completionDate":"2010-01"},{"nctId":"NCT01685242","phase":"Phase 3","title":"A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","isPivotal":true,"enrollment":100,"indication":"Allergic Conjunctivitis","completionDate":"2012-11"},{"nctId":"NCT00257569","phase":"Phase 3","title":"Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Atopic Dermatitis-","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":278,"indication":"Dermatitis, Atopic","completionDate":""},{"nctId":"NCT02756624","phase":"Phase 3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","isPivotal":true,"enrollment":516,"indication":"Healthy Subjects","completionDate":"2016-08"},{"nctId":"NCT03296358","phase":"NA","title":"A Randomized, Double-blinded, Controlled Trial of Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines","status":"COMPLETED","sponsor":"Chulalongkorn University","isPivotal":false,"enrollment":75,"indication":"Urticaria, Allergy","completionDate":"2019-10-31"},{"nctId":"NCT03167216","phase":"EARLY/Phase 1","title":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":20,"indication":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","completionDate":"2022-06-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once daily","formulation":"Tablet, Chewable tablet, Liquid"},"crossReferences":{"chemblId":"CHEMBL1607273"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1855,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"firstApprovalDate":"1995-09-29","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-09-27T00:00:00.000Z","mah":"J AND J CONSUMER INC","brand_name_local":"ZYRTEC","application_number":"NDA020346"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-08-12T00:00:00.000Z","mah":"APOTEX","brand_name_local":null,"application_number":"ANDA207235"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-07-21T00:00:00.000Z","mah":"ONESOURCE SPECIALTY","brand_name_local":null,"application_number":"ANDA205291"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-07-20T00:00:00.000Z","mah":"AUROBINDO PHARMA LTD","brand_name_local":null,"application_number":"ANDA209107"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-03-03T00:00:00.000Z","mah":"TARO","brand_name_local":null,"application_number":"ANDA076601"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-05-20T00:00:00.000Z","mah":"SUN PHARM INDS LTD","brand_name_local":null,"application_number":"ANDA090922"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"regulatorySummaries":{"US_FDA_approval_46776":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"46776","summary_short":"SUN PHARM INDS LTD received FDA approval for Zyrtec on 2025-05-20 under application number ANDA090922.","summary_long":"The FDA granted marketing authorisation to SUN PHARM INDS LTD for Zyrtec on 20 May 2025. The approval was issued under the standard expedited pathway. The approved indication for Zyrtec is listed in the labelling.","key_points":["SUN PHARM INDS LTD received FDA approval for Zyrtec on 2025-05-20.","The approval was issued under the standard expedited pathway.","The approved indication for Zyrtec is listed in the labelling."],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA090922"}],"generated_at":"2026-05-18T08:07:47.838Z"}},"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:40:25.651414+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}